Possible genetic predisposition to lymphedema after breast cancer

Lymphatic Research and Biology

Volumn 10, Issue 1, 2012, Pages 2-13

  Newman, Beth ^a   Lose, Felicity ^b   Kedda, Mary Anne ^a   Francois, Mathias ^c   Ferguson, Kaltin ^b   Janda, Monika ^a   Yates, Patsy ^a   Spurdle, Amanda B ^b   Hayes, Sandra C ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR SOX18; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; ARTICLE; AUSTRALIA; BREAST CANCER; CANCER INVASION; CANCER PATIENT; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; LYMPHEDEMA; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LYMPHATIC SYSTEM; LYMPHEDEMA; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; QUEENSLAND; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859053772     PISSN: 15396851     EISSN: 15578585     Source Type: Journal    
DOI: 10.1089/lrb.2011.0024     Document Type: Article

References (47)

1. Petrek JA, Heelan MC. Incidence of breast carcinoma-related lymphedema. Cancer 1998;83:2776-2781. (Pubitemid 29024266)
2. Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL. Arm edema in breast cancer patients. JNCI 2001;93:96-111. (Pubitemid 32111987)
3. Clark B, Sitzia J, Harlow W. Incidence and risk of arm oedema following treatment for breast cancer: A three-year follow-up study. Q J Med 2005;98:343-348. (Pubitemid 40663122)
4. Foldi E. The treatment of lymphoedema. Cancer 1998;83: 2833-2834.
5. Hayes S, Rye S, Battistuta D, Newman B. Prevalence of upper-body symptoms following breast cancer and its relationship with upper-body function and lymphoedema. Lymphology 2010;43:178-187.
6. Finnane A, Hayes S, Obermair A, Janda M. Quality of life of women with lower-limb lymphoedema following gynaecological cancer. Expert Rev Pharmacoecon Outcomes Res 2011;11:287-297.
7. Petrek JA. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 2001;92:1368-1377. (Pubitemid 32947819)
8. Edwards TL. Prevalence and aetiology of lymphoedema after breast cancer treatment in southern Tasmania. Aust N Z J Surg 2000;70:412-418. (Pubitemid 30367639)
9. Hayes SC, Janda M, Cornish B, Battistutta D, Newman B. Lymphoedema following breast cancer: Incidence, risk factors and effect on upper body function. J Clin Oncol 2008;26:3536-3542.
10. Williams AF, Franks PJ, Moffatt CJ. Lymphoedema: Estimating the size of the problem. Palliat Med 2005;19:300-313. (Pubitemid 40872760)
11. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999;98:769-778. (Pubitemid 29446894)
12. Srinivasan R, Geng X, Yang Y, Wang Y, Mukatira S, Studer M, Porto M, Lagutin O, Oliver G. The nuclear hormone receptor Coup-TFII is required for the initiation and early maintenance of Prox1 expression in lymphatic endothelial cells. Genes Dev 2010;24:696-707.
13. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson D, Talikka M, Rauvala H, Betsholtz C, Alitalo K. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004;5:74-80. (Pubitemid 38081471)
14. Francois M, Caprini A, Hosking B, Orsenigo F, Wilhelm D, Browne C, Paavonen K, Karnezis T, Shayan R, Downes M, Davidson T, Tutt D, Cheah KS, Stacker SA, Muscat GE, Achen MG, Dejana E, Koopman P. Sox18 induces development of the lymphatic vasculature in mice. Nature 2008;456:643-647.
15. Irrthum A, Devriendt K, Chitayat D, Matthijs G, Glade C, Steijlen PM, Fryns JP, Van Steensel MA, Vikkula M. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis- lymphedematelangiectasia. Am J Hum Genet 2003;72:1470-1478. (Pubitemid 36628386)
16. Ferrell RE, Levinson KL, Esman JH, Kimak MA, Lawrence EC, Barmada MM, Finegold DN. Hereditary lymphedema: Evidence for linkage and genetic heterogeneity. Hum Mol Genet 1998;7:2073-2078. (Pubitemid 28546416)
17. Fang J, Dagenais SL, Erickson RP, Arlt MF, Glynn MW, Gorski JL, Seaver LH, Glover TW. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet 2000;67:1382-1388.
18. Evans A, Bell R, Brice G, Comeglio P, Lipede C, Jeffery S, Mortimer P, Sarfarazi M, Child A. Identification of eight novel VEGFR-3 mutations in families with primary congenital lymphoedema. J Med Genet 2003;40:697-703. (Pubitemid 37100704)
19. Ferrell R, Finegold DN. Research perspectives in inherited lymphedema: An update. Ann NY Acad Sci 2008;1131:134-139. (Pubitemid 351758510)
20. Butler MG, Isogai S, Weinstein BM. Lymphatic development. Birth Defects Res C Embryo Today 2009;87:222-231.
21. Kurebayashi S, Ueda E, Sakaue M, Patel DD, Medvedev A, Zhang F, Jetten AM. Retinoid-related orphan receptor gamma (RORgamma) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis. Proc Natl Acad Sci USA 2000;97:10132-10137.
22. Jin D, Harada K, Ohnishi S, Yamahara K, Kangawa K, Nagaya N. Adrenomedullin induces lymphangiogenesis and ameliorates secondary lymphoedema. Cardiovasc Res 2008;80:339-345.
23. Hayes S, Cornish B, Newman B. Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6- month follow-up. Breast Cancer Res Treat 2005;89:221-226. (Pubitemid 43293068)
24. Barrett J, Fry B, Maller J, Daly M. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265. (Pubitemid 40202029)
25. Lose F, Nagle C, O'Mara T, Batra J, Bolton K, Song H, Ramus S, Gentry-Mahara A, Menon U, Gayther S, Pharoah P, Kedda M, Spurdle A. Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecol Oncol 2010;119:479-483.
26. Amigo J, Salas A, Phillips C, Carracedo A. SPSmart: Adapting population based SNP genotype databases for fast and comprehensive web access. BMC Bioinformatics 2008;9:428.
27. Johnson A, Handsaker R, Pulit S, Nizzari M, O'Donnell C, de Bakker P. SNAP: A web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008;24:2938-2939.
28. Ahmed S, Thomas G, Ghoussaini M, Healey CS, Humphreys MK, Platte R, Morrison J, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 2009;41:585-590.
29. Hayes SC, Janda M, Cornish B, Battistutta D, Newman B. Lymphoedema secondary to breast cancer: How choice of measure influences diagnosis, prevalence and identifiable risk factors. Lymphology 2008;41:18-28. (Pubitemid 351747151)
30. Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett 2006;580:2879-2887. (Pubitemid 43729175)
31. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997;276:1423-1425. (Pubitemid 27235412)
32. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG, Stacker SA, Alitalo K. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J2001;20:1223-1231. (Pubitemid 32233963)
33. Rutkowski JM, Moya M, Johannes J, Goldman J, Swartz MA. Secondary lymphedema in the mouse tail: Lymphatic hyperplasia, VEGF-C upregulation, and the protective role of MMP-9. Microvasc Res 2006;72:161-171. (Pubitemid 44692751)
34. Kim H Dumont DJ. Molecular mechanisms in lymphangiogenesis: Model systems and implications in human disease. Clin Genet 2003;64:282-292.
35. Tammela T Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell 2010;140:460-476.
36. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 2000;25:153-159. (Pubitemid 30394984)
37. Irrthum A, Karkkainen M, Devriendt K, Alitalo K, Vikkula M. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet 2000;67:295-301. (Pubitemid 30616736)
38. Zongli Xu Jack A. Taylor. SNPinfo: Integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res http://manticore.niehs.nih.gov/snpfunc.htm. 2009.
39. Hiard S, Charlier C, Coppieters W, Georges M, Baurain D. Patrocles: A database of polymorphic miRNA-mediated gene regulation in vertebrates. Nucleic Acids Res 2010;38:D640-651.
40. Galland F, Karamysheva A, Pebusque MJ, Borg JP, Rottapel R, Dubreuil P, Rosnet O, Birnbaum D. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. Oncogene 1993;8:1233-1240. (Pubitemid 23129845)
41. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-249.
42. Medvedev A, Chistokhina A, Hirose T, Jetten AM. Genomic structure and chromosomal mapping of the nuclear orphan receptorROR gamma (RORC) gene. Genomics 1997;46:93-102. (Pubitemid 27527696)
43. Marino D, Dabouras V, Brandli A, Detmar M. A role for alltrans- retinoic acid in the early steps of lymphatic vasculature development. J Vascul Res 2011;48:236-251.
44. He YW, Deftos ML, Ojala EW, Bevan MJ. RORgamma t, a novel isoform of an orphan receptor, negatively regulates Fas ligand expression and IL-2 production in T cells. Immunity 1998;9:797-806. (Pubitemid 29024459)
45. Johnson NC, Dillard ME, Baluk P, McDonald DM, Harvey NL, Frase SL, Oliver G. Lymphatic endothelial cell identity is reversible and its maintenance requires Prox1 activity. Genes Dev 2008;22:3282-3291.
46. Hayes S, Rye S, Round T, Lopez J, Saunders C, Pyke C, Bashford J, Battistutta D, Newman B. Prevalence and prognostic significance of secondary lymphedema following breast cancer. Lymph Res Biol 2011;9:135-141.
47. Stout Gergich NL, Pfalzer LA, McGarvey C, Springer B, Gerber LH, Soballe P. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer 2008;112:2809-2819. (Pubitemid 351969228)